Patient Access & Affordability

Patient Access & Affordability

Four-times-a-year AMVUTTRA is accessible and affordable for most patients, regardless of insurance type. AMVUTTRA is HCP-administered once every 3 months.

99%

of patients have confirmed coverage for AMVUTTRA*

>65%

of patients treated with AMVUTTRA have no out-of-pocket costs*

*As of December 29, 2023.

For many patients with commercial insurance or Medicare, AMVUTTRA is covered under the medical benefit and not the pharmacy benefit.

To learn more, visit www.AlnylamAssist.com

Stay informed

Receive helpful information for you and your patients.

Sign up

Find a treatment center

Locate a treatment center closest to your patients.

View the directory

Up next Resources & Links  

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

In a study of patients with hATTR-PN, the most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

In a study of patients with ATTR-CM, no new safety issues were identified.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

AMVUTTRA® (vutrisiran) is indicated for the treatment of the:

  • cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
  • polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.